Biocon has secured approval from the European Commission to sell its biosimilar breast cancer drug, Pebrilzo®, in the European Union. This decision allows the company to offer a new treatment option for patients with HER2-positive breast cancer across multiple disease stages.
- Biocon’s Pebrilzo® is a biosimilar for pertuzumab, used in treating HER2-positive breast cancer.
- The European Commission granted marketing authorization following a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
- This biosimilar is the first to receive approval under the EMA’s new tailored clinical approach.
- Pebrilzo® is now Biocon’s fifth oncology biosimilar approved in both Europe and the United States.
- The approval strengthens Biocon’s global oncology portfolio and commitment to affordable cancer therapies.
What is Pebrilzo® and how does it work?
Pebrilzo® is a biosimilar version of pertuzumab, a drug used to treat HER2-positive breast cancer. HER2-positive breast cancer is a type of cancer where the cancer cells have higher levels of the HER2 protein, which promotes the growth of cancer cells. Pertuzumab works by targeting this protein, helping to slow or stop the growth of the cancer.
What does the European Commission’s approval mean?
The European Commission’s approval means that Pebrilzo® can now be marketed and sold across all member countries of the European Union. This approval follows a thorough evaluation by the European Medicines Agency (EMA), which assessed the drug’s quality, safety, and effectiveness.
What role does the European Medicines Agency play?
The European Medicines Agency (EMA) is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the EU. Its Committee for Medicinal Products for Human Use (CHMP) reviews data on new drugs and provides opinions on whether they should be authorized for sale. The positive opinion from CHMP was a key step before the European Commission granted final approval.
Why is this approval significant for Biocon?
This approval marks Pebrilzo® as the first biosimilar to receive marketing authorization under the EMA’s new tailored clinical approach. It also becomes Biocon’s fifth oncology biosimilar approved in both Europe and the United States. This expands Biocon’s global oncology portfolio and demonstrates the company’s commitment to making high-quality, affordable biologic therapies accessible to patients with HER2-positive breast cancer.
How does this impact patients and the market?
With this approval, patients in the European Union will have access to a more affordable treatment option for HER2-positive breast cancer. Biosimilars like Pebrilzo® often cost less than original biologic drugs, which can help reduce healthcare costs and improve treatment availability. For the market, this approval strengthens competition and encourages innovation in cancer therapies.
Frequently Asked Questions
Q: What is a biosimilar?
A biosimilar is a medicine that is highly similar to an already approved biological medicine, known as the reference product. It has no meaningful differences in terms of safety, quality, and effectiveness.
Q: What is HER2-positive breast cancer?
HER2-positive breast cancer is a type of breast cancer where cancer cells have more HER2 receptors, which promote cancer growth. Treatments targeting HER2 can help control the disease.
Q: How does the EMA’s new tailored clinical approach affect drug approval?
The EMA’s new tailored clinical approach allows for more flexible and efficient evaluation of biosimilars, potentially speeding up the approval process while ensuring safety and efficacy.
Q: Will Pebrilzo® be available outside Europe?
Biocon has already received approval for its oncology biosimilars, including pertuzumab, in the United States, and this approval adds to its global availability.
Biocon’s recent approval by the European Commission is a milestone in the fight against breast cancer, offering hope for more accessible treatment options across Europe.

